Non-Allergic/Mixed Rhinitis: Recent Study Findings Reveal New Treatment Option

Share Article

Epidemiological reports estimate that nearly 38MM US individuals suffer from non-allergic and/or mixed rhinitis. Treatment options for these conditions have historically been limited to traditional antihistamines and nasal corticosteroids, but a recent study funded by Dynova Laboratories identified a safe and highly effective option for sufferers that begins providing symptom relief in under one minute.

“The study results demonstrate that Sinus Buster is a powerful solution for sinus congestion, pressure and headaches that not only provides immediate relief, but also provides sustained relief throughout the course of the two-week treatment period.”

Epidemiological reports indicate that the US prevalence of non-allergic rhinitis(NAR) totals approximately 19MM individuals; however, due to its frequent tandem occurrence with allergic rhinitis, nearly twice that number may actually suffer from NAR and/or mixed rhinitis(MR). Due to the vast etiology involved with NAR/MR, treatment options for the condition have historically been limited to traditional antihistamines and nasal corticosteroids. However, a recent clinical trial funded by Dynova Laboratories has identified a new highly effective option for sufferers.

In a recent clinical study published in the Annals of Asthma, Allergy and Immunology, researchers found that NAR and MR sufferers could achieve rapid onset of symptom relief (average time to first relief of 52.6 seconds (p<.01)) and significant improvement in TNSS by twice daily use of an all-natural intranasal capsaicin and eucalyptol preparation (ICX72), available publicly as Sinus Buster™.

Lead researcher Dr. Jonathan Bernstein, Professor of Medicine at the University of Cincinnati, Department of Internal Medicine, Division of Immunology/Allergy section, stated, “The study results demonstrate that Sinus Buster is a powerful solution for sinus congestion, pressure and headaches that not only provides immediate relief, but also provides sustained relief throughout the course of the two-week treatment period.” This double-blind, randomized, placebo-controlled study investigated the efficacy and safety of Sinus Buster compared to placebo when administered continuously over a two week period in subjects with a significant component of NAR. Thirty-three of the 42 participants had a diagnosis of MR and 9 had a NAR diagnosis; diagnoses were evenly distributed between groups. Additionally, ICX72 subjects experienced continued relief over the 2 week study period, with significantly greater improvement in nasal congestion, sinus pressure, sinus pain and headache compared to placebo (p<.01).

ICX72 subjects experienced no rebound congestion and demonstrated an improvement in olfaction versus placebo at end of study. “Capsaicin’s safety and efficacy has been studied extensively for the treatment of sinusitis, allergic rhinitis and headache, but this is the first controlled clinical trial to demonstrate that ICX72 (Sinus Buster™) provides a rapid onset of relief for rhinitis subjects with a non-allergic component, while also providing safe, sustained relief over the course of the two week treatment period,” said Dr. Bernstein. “The study findings represent a significant break into the search for safe and effective long-term treatment options for NAR/MR sufferers.”

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tricia Beninghof
Dynova Labs
973-539-1341
Email >